Alkem Laboratories Limited FII & DII Activity

Today's Institutional Flow

FII cash net inflow stands at ₹871.83 Cr while DII cash net inflow is ₹643.35 Cr, indicating a stronger foreign institutional appetite amid broader market optimism and portfolio rebalancing efforts across mid‑cap and large‑cap segments during Q4 period. The combined cash inflow of ₹1,515.18 Cr reflects positive participation across equities, bonds and derivatives, and underscores a notable shift from earlier week‑long outflows. No block or bulk transactions are recorded for Alkem Laboratories Limited, confirming that the observed flow is purely attributable to routine market‑maker activity.

Trend vs 5-Day Average

The day’s FII cash surge contrasts with a five‑day average outflow of ₹‑894.74 Cr, marking a reversal in foreign investor sentiment and suggesting a tentative re‑entry into risk‑on positions. Conversely, DII cash continues to build on a five‑day average of ₹2,592.03 Cr, showing sustained domestic buying pressure that supports overall sector liquidity.

F&O Positioning Data

FII net exposure in futures and options rises by ₹643,395 Cr, illustrating significant derivative activity that may be linked to hedging or speculative strategies ahead of upcoming earnings releases. Their index futures positions are marginally net long, with a long‑to‑short ratio of 1.2, indicating a modest bias toward bullish market moves.

Healthcare Sector Flow

Overall, the healthcare sector sees a modest net inflow from FII and a continued net inflow from DII over the recent period, reinforcing the view that both foreign and domestic investors retain confidence in the industry’s growth trajectory.